Already a member? Sign in
Selegiline is an antidepressant and anti-Parkinson's agent. Orally it is used as an adjunct to levodopa/carbidopa therapy for Parkinson's disease; transdermally it is used for major depressive disorder. Off label it is used for ADHD; negative symptoms of schizophrenia and extrapyramidal symptoms.
| Purpose | # of patients |
# of patients with evaluations
Efficacy
|
Major | Moderate | Slight | None | Can’t tell |
|---|---|---|---|---|---|---|---|
| Parkinson's Disease | 231 | 44 |
|
|
|
|
|
| Depressed mood | 20 | 15 |
|
|
|
|
|
| Stiffness/Spasticity | 11 | 1 |
|
||||
| Other | 10 | 4 |
|
|
|
||
| Treat my mood condition(s) | 9 | 3 |
|
|
|||
| Major Depressive Disorder | 8 | 4 |
|
|
See all 224 patients currently taking Selegiline
Mouse over the table for more information
Commonly reported side effects, conditions, and hospitalizations associated with Selegiline
| Difficulty falling asleep | 4 | |
|---|---|---|
| Dietary restrictions | 3 | |
| Insomnia | 3 | |
| Tiredness | 2 | |
| Prostate problems | 2 | |
| Suicidal | 2 | |
| See all 32 reported side effects ▼ | ||
Frequently reported dosages based on patients currently taking Selegiline. See all 25 dosages ►
| Reason | # Patients | Percentage of patients | |
|---|---|---|---|
| Did not seem to work | 49 | ||
| Doctor's advice | 41 | ||
| Side effects too severe | 26 | ||
| Other | 22 | ||
| Personal research | 11 | ||
| Expense | 6 | ||
| Not indicated | 3 | ||
| Course of treatment ended | 2 | ||
| Change in health plan coverage | 2 |
Adherence
Taking treatment as prescribed
Adherence of Selegiline
Always |
60 | 80% |
|
|---|---|---|---|
Usually |
8 | 11% |
|
Sometimes |
2 | 3% |
|
Never |
5 | 7% |
|
Burden
Difficulty being on treatment
Burden of Selegiline
Very |
5 | 7% |
|
|---|---|---|---|
Somewhat |
5 | 7% |
|
A little |
12 | 16% |
|
Not at all |
53 | 71% |
|
Cost
Paid out of pocket
Cost of Selegiline
$200+ |
2 | 4% |
|
|---|---|---|---|
$100-199 |
1 | 2% |
|
$50-99 |
7 | 15% |
|
$25-49 |
14 | 29% |
|
< $25 |
24 | 50% |
|
See more information, including instructions, precautions, side effects, and interactions.
Report created on February 09, 2012.